BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a Research and Development Agreement ("Agreement") with Rohto Pharmaceutical Company, Ltd. ("Rohto"). Under the Agreement, BRT has been engaged to provide stem cell research and development services.
Rohto is a Japanese global pharmaceutical company with approximately $1.3 billion in sales that develops new technology for the medical and cosmetics markets.
"BioRestorative Therapies has expertise in cell biology with considerable skills in culturing stem cells, and we are delighted that Rohto has selected BRT to assist it with its cell based therapeutic program," said Mark Weinreb, Chief Executive Officer of BRT. "We look forward to a productive relationship with this new prestigious partner."
New research sheds light on how GLP-1 obesity drugs may change food cravings